AI in Biopharma: Transforming Drug Discovery and Bioprocessing

The average drug development timeline, from discovery to the commercial launch of a new drug, is between 12 and 15 years. To overcome long timelines, high demand, clinical trial failures, and complex biomanufacturing processes, the industry is adopting AI.

Advances in gen AI, neural networks, and LLMs enable improvement in predictive AI models. These predictive models can save significant time and costs in drug development while meeting the expected accuracy and quality levels in clinical outcomes. Biopharma companies are adopting AI-driven platforms to accelerate drug-target discovery, lead identification, lead optimization, and clinical trials across modalities. AI is also transforming advanced therapeutics, clinical decisions, regulatory assistance, and drug delivery system design and formulation.

This report analyzes AI’s role in biopharma and explores AI’s technology advances, impact, and future evolution in drug discovery and bioprocessing.